The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–236 of 236
Alizadeh, H., Jaafar, H., Rajnics, P., KHAN, M. I., & Kajtár, B. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.10.002 · Cited by 34
Wang, W., Tang, G., Cortes, J. E., Liu, H., Ai, D., Yin, C. C., Li, S., Khoury, J. D., Bueso-Ramos, C., Medeiros, L. J., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0128-2 · Cited by 34
Saußele, S., Hehlmann, R., Fabarius, A. C., Jeromin, S., Proetel, U., Rinaldetti, S. L., Kohlbrenner, K., Einsele, H., Falge, C., Kanz, L., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0055-7 · Cited by 33
Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib
Oweini, H., Otrock, Z. K., Mahfouz, R. A., & Bazarbachi, A. A. (2010) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-010-1501-6 · Cited by 32
Berman, E., Girotra, M., Cheng, C., Chanel, S. M., Maki, R. G., Shelat, M., Strausś, H. W., Fleisher, M., Heller, G., & Farooki, A. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.02.005 · Cited by 32
Self-citationBreccia, M., Cannella, L., Montefusco, E., Frustaci, A. M., Pacilli, M., & Alimena, G. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.07.022 · Cited by 32
Quintás‐Cardama, A., Cortes, J. E., & Kantarjian, H. M. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.s.003 · Cited by 31
Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia
Aleem, A. (2009) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/s1658-3876(09)50026-x · Cited by 31
Annunziata, M., Bonifacio, M., Breccia, M., Castagnetti, F., Gozzini, A., Iurlo, A., Pregno, P., Stagno, F., & Specchia, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00883 · Cited by 30
Chelysheva, E., Aleshin, S., Polushkina, E., Shmakov, R. G., Shohin, I. E., Chilov, G. G., & Turkina, A. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.027 · Cited by 29
Soverini, S., Benedittis, C. D., Castagnetti, F., Gugliotta, G., Mancini, M., Bavaro, L., Poláková, K. M., Linhartová, J., Iurlo, A., Russo, D., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2635-0 · Cited by 28
Petiti, J., Iacono, M. L., Dragani, M., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051457 · Cited by 27
Lasica, M., Willcox, A., Burbury, K., Ross, D. M., Branford, S., Butler, J., Filshie, R., Januszewicz, H., Joske, D. J. L., Mills, A. K., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1551533 · Cited by 26
Sakurai, M., Kikuchi, T., Karigane, D., Kasahara, H., Matsuki, E., Hashida, R., Yamane, Y., Abe, R., Koda, Y., Toyama, T., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02596-z · Cited by 26
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
Shanmuganathan, N., & Hughes, T. P. (2018) · Blood · doi:10.1182/blood-2018-05-848630 · Cited by 25
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
Shanmuganathan, N., & Hughes, T. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.168 · Cited by 25
Do, Y. R., Kwak, J., Kim, J. A., Kim, H. J., Chung, J. S., Shin, H., Kim, S., Bunworasate, U., Choi, C. W., Zang, D. Y., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16381 · Cited by 25
Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib
Casavecchia, G., Galderisi, M., Novo, G., Gravina, M., Santoro, C., Agricola, E., Capalbo, S. F., Zicchino, S., Cameli, M., Gennaro, L. D., et al. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09926-y · Cited by 25
Balsat, M., Etienne, M., Elhamri, M., Hayette, S., Salles, G. A., & Thomas, X. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13167 · Cited by 24
Landstrom, A. P., Ketterling, R. P., Knudson, R. A., & Tefferi, A. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600783551 · Cited by 21
Experience with dasatinib and nilotinib use in pregnancy
Barkoulas, T., & Hall, P. D. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217692399 · Cited by 21
Tokuhira, M., Kimura, Y., Sugimoto, K., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1093-8 · Cited by 21
Pregnancy Outcomes in Chronic Myeloid Leukemia: A Single Center Experience
Madabhavi, I., Sarkar, M. S., Modi, M., & Kadakol, N. (2019) · Journal of Global Oncology · doi:10.1200/jgo.18.00211 · Cited by 21
Kim, D., Saußele, S., Williams, L. A., Mohamed, H., Rong, Y., Zyczynski, T. M., Pinilla-Ibarz, J. A., & Abruzzese, E. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3295-8 · Cited by 20
Santos, F. P. D. S., Alvarado, Y., Kantarjian, H. M., Verma, D., O'Brien, S. M., Mattiuzzi, G. N., Ravandi, F., Borthakur, G. M., & Cortes, J. E. (2010) · Cancer · doi:10.1002/cncr.25533 · Cited by 19
Hoffmann, V. S., Hasford, J., Deininger, M. W., Cortes, J. E., Baccarani, M., & Hehlmann, R. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2385-7 · Cited by 18
Self-citationStaley, E. M., Simmons, S. C., Feldman, A. Z., Lorenz, R. G., Marques, M. B., Williams, L. A., Zheng, X. L., & Pham, H. P. (2017) · Transfusion · doi:10.1111/trf.14448 · Cited by 18
Karimata, K., Masuko, M., Ushiki, T., et al. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.4481 · Cited by 17
Assunção, P. M., Lana, T. P., Delamain, M. T., Duarte, G. O., Zulli, R., Lorand-Metze, I. G. H., Souza, C. A. D., Paula, E. V. D., & Pagnano, K. B. B. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.004 · Cited by 17
Bidet, A., Dulucq, S., Smol, T., Marceau‐Renaut, A., Morisset, S., Coiteux, V., Mp, N.-W., Nicolini, F. E., Tigaud, I., Luquet, I., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.208801 · Cited by 17
Ghalaut, V. S., Prakash, G., Bansal, P., Dahiya, K., Dokwal, S., Ghalaut, P. S., Bala, M., & Dhankhar, R. (2013) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155213500686 · Cited by 16
Akard, L. P., Cortes, J. E., Albitar, M. X., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0584-oa · Cited by 15
Douet‐Guilbert, N., Morel, F., Charpentier, T. L., et al. (2004) · PubMed · Cited by 15
Naqvi, K. Z., Cortes, J. E., Luthra, R., O'Brien, S. M., Wierda, W. G., Borthakur, G. M., Kadia, T. M., Garcia‐Manero, G., Ravandi, F., Rios, M. B., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2422-6 · Cited by 15
Self-citationSerpa, M. G., Sanabani, S. S., Bendit, I., Seguro, F. S., Xavier, F., Barroso, C. B., Conchon, M., & Dorlhiac‐Llacer, P. E. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s6413 · Cited by 10
Crampe, M., Haslam, K., Kelly, J., et al. (2016) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2016.02.002 · Cited by 6
Cited by
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Self-citationAlves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Jiang, Q., Li, Z., Qin, Y., Li, W., Xu, N., Liu, B., Zhang, Y., Meng, L., Zhu, H., Du, X., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01334-z · Cited by 102
Self-citationBidikian, A., Jabbour, E., Issa, G. C., Short, N. J., Sasaki, K., & Kantarjian, H. (2023) · American Journal of Hematology · doi:10.1002/ajh.26836 · Cited by 32
Gener-Ricos, G., Haddad, F. G., Sasaki, K., Issa, G. C., Skinner, J., Masarova, L., Borthakur, G., Alvarado, Y., Garcia-Manero, G., Jabbour, E., et al. (2023) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2023.05.009 · Cited by 30
Metadata
- Authors
- Deininger, M. W., Shah, N. P., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., DeAngelo, D. J., Gotlib, J., Hobbs, G., Maness, L., Mead, M., Metheny, L., Mohan, S., Moore, J. O., Naqvi, K., Oehler, V., Pallera, A. M., Patnaik, M., Pratz, K., Pusic, I., Rose, M. G., Smith, B. D., Snyder, D. S., Sweet, K. L., Talpaz, M., Thompson, J., Yang, D. T., Gregory, K. M., & Sundar, H.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2020-10
- Volume
- 18
- Issue
- 10
- Pages
- 1385-1415
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W3092607363
- Cited by
- 262
- References
- 236
- FWCI
- 24.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.